1. Introduction {#sec1}
===============

Neuroleptic malignant syndrome (NMS) is a life-threatening neurological emergency that occurs following use of neuroleptic drugs and other dopamine antagonists or termination of a dopamine agonist and characterized by altered mental state, fever, rigidity and autonomic dysfunction. Although typical neuroleptics exhibiting an antagonist effect on dopamine receptors are frequently involved in the etiology, there are also reports in the literature of cases of NMS caused by drugs from various different groups.[@bib1], [@bib2] Diagnostic criteria are used to overcome the diagnostic difficulty in NMS ([Table 1](#tbl1){ref-type="table"}).[@bib3] There are no specific laboratory findings used in diagnosis, but in addition to increasing creatine kinase (CK) associated with muscle destruction, accompanying leukocytosis, increased serum aminotransferases (AST and ALT), electrolyte anomalies (hyperkalemia, hypo-hypernatremia or hypocalcemia), increased lactate dehydrogenase (LDH) and metabolic acidosis may be seen.[@bib4]Table 1Diagnostic criteria for NMS.Table 1CriteriaCharacteristicsAt leastHistory of drug use-Use of one antipsychotic-Use of one dopamine antagonist-Recent termination of treatment with one dopamine agonist1Major criteria-Hyperthermia (37.5° or above)-Muscular rigidity,-Creatine kinase (CK) levels over 3 times above normal2Minor criteria-Altered mental state,-Extrapyramidal findings, Autonomic instability,-Respiration problems,-Leukocytosis4

The first stage in the treatment of NMS is to stop the agent responsible or to resume the discontinued dopamine agonist. In the second stage, intensive supportive therapy is applied. Dantrolene, a centrally acting muscle relaxant recommended for specific therapy but lacking sufficient levels of evidence for its efficacy, and the dopamine agonist bromocriptine and amantadine are pharmacological agents capable of use in addition to supportive therapy.[@bib5], [@bib6] Mortality rates associated with complications of NMS, such as rhabdomyolysis, acute kidney failure, respiratory failure, cardiovascular collapse, aspiration pneumonia and disseminated intravascular coagulation, approach 50%, but this decreases to approximately 5% with adequate supportive therapy in cases without complications.[@bib7] Early commencement of treatment through early diagnosis in emergency departments and the determination of prognostic factors affecting mortality are therefore important in terms of survival. Since the incidence of NMS in the community is low, evidence-based data concerning the epidemiology and clinical and pharmacological risk factors are limited. Our purpose was therefore to evaluate the epidemiological and clinical characteristics of patients diagnosed with NMS in our hospital and, in particular, to identify prognostic factors capable of affecting mortality by comparing the clinical and laboratory features of death and survived cases.

2. Materials and methods {#sec2}
========================

In this cross-sectional, descriptive study, following receipt of ethical committee approval, patients aged 18 or over presenting to the Karadeniz Technical University Faculty of Medicine Emergency Department in 2006--2016 and diagnosed with NMS were identified by scanning their ICD-10 codes from the hospital computer software system, and patient files obtained from the archive were examined retrospectively. Cases with incorrect ICD-10 entries and patients with incomplete record data were excluded. Patients\' ICD-10 diagnoses were confirmed on the bases of the NMS criteria shown in [Table 1](#tbl1){ref-type="table"}. The diagnosis of NMS was made in the presence of at least two of the major and four minor diagnostic criteria. Cases\' demographic characteristics, existing diseases, clinical and laboratory findings, all drugs used, lengths of stay in hospital and survival were evaluated. Cases were divided into two groups on the bases of clinical outcomes *death* and *recovery*. All data were transferred to and analyzed on IBM Statistical Package for the Social Sciences 23.0 (IBM SPSS Inc., Chicago, IL, USA) software. The Mann Whitney *U* test was used to compare the two groups\' non-parametric data, and p values ≤ 0.05 were regarded as statistically significant.

3. Results {#sec3}
==========

Records were available for all 18 patients diagnosed with NMS among the 505,520 patients presenting to the emergency department in 2006--2016. According to our records, the rate of NMS among patients presenting to our hospital in the previous 10 years was 0.004%.

The distribution of patients\' clinical characteristics is shown in [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}. Half of the patients were women, and the general median age was 43.5 (IQR, 30.2--67.2). The most common existing chronic diseases among the patients were schizophrenia at 27.8% (n = 5), Parkinson\'s disease at 22.2% (n = 4), and mental retardation at 16.7% (n = 3), with lower incidences of substance dependence, dementia, bipolar disorder, acute psychosis and delirium. A history of use of two or more drugs was present in 88.9% (n = 16) of cases, and of antipsychotic drug use in 77.8% (n = 14). Drug use was at therapeutic doses in all NMS cases. The most common antipsychotic agents used by NMS patients were atypical antipsychotic agents (78.6%, n = 11).Table 2Characteristics of NMS cases.Table 2No.Age, sex (M: Male, F: Female)DiseaseDrugs usedTA (mmHg)Pulse (min)Temperature (°C)GCSClinical symptoms and findingsOutcomeLength of stay in hospital (Day)Causes of death147, FSchizophreniaAlprazolam, quetiapine, aripiprazole, paliperidone164/12311338.68Muscular rigidity, sweating, dysphagia, tremor, incontinence, altered consciousness, mutismDeath10Sepsis275, MSchizophreniaBiperiden, mirtazapine, paroxetine, amisulpride, clozapine, risperidone160/14017039.09Muscular rigidity, sweating, dysphagia, tremor, incontinence, altered consciousness, mutismDeath2Respiratory failure376, FParkinsonLevodopa (withdrwal), pramipexole, gabapentin, paroxetine, amitriptyline180/10014039.310Muscular rigidity, sweating, tremor, altered consciousness, mutismDeath42Sepsis442, MMental retardationBiperiden, olanzapine170/10011738.412Muscular rigidity, sweating, tremor, altered consciousnessRecovery32543, FBipolar disorderBiperiden, amitriptyline, lithium, phenothiazine, chlorpromazine, quetiapine90/6012239.111Muscular rigidity, sweating, tremor, altered consciousness, mutismRecovery19664, FBipolar disorderValproic acid, lorazepam, haloperidol, quetiapine, olanzapine140/8010838.013Muscular rigidity, tremor, altered consciousness,Recovery11720, FMental retardationRisperidone, quetiapine110/808039.011Muscular rigidity, dysphagia, tremor, incontinence altered consciousness, mutismRecovery47844, MSchizophrenia\
+Substance dependenceAmisulpride120/708438.612Muscular rigidity, sweating, tremor, altered consciousness, mutismRecovery31918, FSchizophrenia\
+acute psychosisClonazepam, amisulpride, olanzapine100/8011238.212Muscular rigidity, sweating, tremor, altered consciousness, mutismRecovery221032, MSubstance dependenceLorazepam, quetiapine110/7092388Muscular rigidity, sweating, altered consciousness, mutismRecovery541125, MMental retardationLorazepam, amisulpride140/908837.913Muscular rigidity, sweating, dysphagia, altered consciousness, mutismRecovery191240, FSchizophreniaBiperiden, mirtazapine, olanzapine100/6013038.513Altered consciousness mutismRecovery921346, MDeliriumHaloperidol, olanzapine145/9012538.512sweating, dysphagia, incontinence, altered consciousness, mutismRecovery81423, KAcute psychosisLorazepam, quetiapine, risperidone160/9014039.011Muscular rigidity, tremor, altered consciousness, mutismRecovery331532,MNo characteristicMetoclopramide140/10012040.010Muscular rigidity, sweating, dysphagia, tremor, incontinence, altered consciousness, mutismRecovery201679, MDementia\
+Parkinson\
+AlzheimerLevodopa (withdrwal), pramipexole150/10011238.212Muscular rigidity, sweating, dysphagia, altered consciousness, mutismRecovery101774, FParkinsonLevodopa, paroxetine, quetiapine150/1008137.710Muscular rigidity, sweating, dysphagia, tremor, altered consciousness, mutismRecovery111865, MParkinsonLevodopa (withdrwal), paroxetine90/5014440.07Muscular rigidity, sweating, dysphagia, altered consciousness, mutismRecovery9Table 3Distribution of clinical symptoms and findings in NMS cases.Table 3n%n%Hyperthermia18100.0Tremor1161.1Muscular rigidity1794.4Dysphagia1055.6Altered consciousness1583.3Hypertension950.0Sweating1583.3Incontinence527.8Mutism1583.3Hypotension316.7Tachycardia1372.2Tremor1161.1

In addition to antipsychotic drugs such as quetiapine, clozapine, risperidone, amisulpride, and haloperidol, the medications leading to the development of NMS also included drugs affecting the central nervous system, such as paroxetine, amitriptyline and lithium. NMS developed following discontinuation of levodopa in three cases and use of metoclopramide in one case ([Table 2](#tbl2){ref-type="table"}). Among the three fatal cases of NMS, two cases used more than one neuroleptic agents and a 76-year-old woman with Parkinson\'s disease used no neuroleptic medication, but NMS developed in association with withdrawal of levodopa and multi-drug use consisting of amitriptyline, pramipexole, gabapentin and paroxetine.

When the death (n = 3) and recovery (n = 15) groups were compared in terms of clinical and laboratory characteristics, statistically significant differences were observed in terms of age, systolic and diastolic blood pressure, blood urea nitrogen (BUN), serum creatine kinase (CK) and mean platelet volume (MPV) values ([Table 4](#tbl4){ref-type="table"}) (**p** ≤ **0.05)**.Table 4Clinical and laboratory findings of groups in NMS.Table 4GroupspDeath (n = 3)Recovery (n = 15)**Clinical characteristics (MD, Min-max)**Age75 (47--76)42 (18--79)**0.05**GCS9 (8--10)12 (7--13)0.054Hearth rate (bpm)140 (113--170)112 (80--144)0.097SBP (mmHg)164 (160--180)140 (90--170)**0.01**DBP (mmHg)123 (100--140)80 (50--100)**0.01**Temperature (C°)39 (38.6--39.3)38.5 (38--40)0.191Length of hospital stay (Day)10 (2--42)20 (8--92)0.34**Laboratory findings (MD, Min-max)**Glucose\
*NR:74-110 mg/dL*139 (108--155)117 (73--349)0.514BUN\
*NR:6-20 mg/dL*42 (27--71)18 (7--35)**0.024**Cre\
*NR:0.5-0.9 mg/dL*1.36 (0.91--2.2)0.7 (0.39--1.70)0.137CK\
*NR:38-176 U/L*5543 (2702--10343)1720 (700--3496)**0.021**AST\
*NR:0-35 U/L*75 (56--94)74 (70--118)0.374ALT\
*NR: 0-45 U/L*54 (3--106)54 (29--94)0.373Troponin\
*NR:* \< *14 ng/mL*88.7 (47--538)40 (4.2--321)0.930Myoglobin\
*NR: 0-85 ng/mL*983 (870--3000)511 (32--3147)0.311CK-MB\
*NR: 0 - 4.8 U/L*16.1 (5.5--25.8)8.7 (2.2--181)0.638Lactate\
*NR: 4.5-19.8 mg/dL*15.5 (11--20)7.78 (7--10.24)0.064LDH\
*NR:122-222 U/L*620 (384--669)403 (165--620)0.097WBC\
*NR:4800-10800 per μL*15,900 (14,027--22,270)10,000 (1000--26,200)0.260Hemoglobin\
*NR:12-17 g/dL*13.5 (10.1--16)12.6 (9--15.7)0.406Platelet\
*NR:130-400 x 10*^*3*^*/μL*162 (154--327)230 (51--474)0.767MPV\
*NR: 7.4-11 fL*13 (10.3--13.8)8.7 (6.2--11.5)**0.021**RDW\
*NR: 11.6-16.5(%)*14.3 (13.3--16.1)14.2 (12.3--21.5)0.767NLR11.2 (3--27.9)7.5 (1--32.3)0.514[^1][^2]

4. Discussion {#sec4}
=============

Our study is one of the largest cohort of NMS patients from Turkey. According to results of this study, both neuroleptic and non-neuroleptic drug use were the causes of NMS. Contrary to common belief, atypical antipsychotic drug use was most commonly observed as the cause of NMS in this study, and also we found that advanced age and high CK, BUN and MPV values can be potential risk factors for mortality.

Factors such as age and sex affect the incidence of NMS in addition to various clinical and pharmacological factors. The incidence of NMS among neuroleptic users therefore ranges between 0.024% and 3%.[@bib8], [@bib9] There are several reasons for this, such as the population selected and the different diagnostic criteria used. Since ICD-10 coding of subjects using neuroleptics was not possible in our hospital\'s data recording system we determined the rate as a proportion among all populations. There is no consensus in the literature concerning gender as a potential risk factor for NMS, although the general opinion in the 1980s was that it is more common in males, the reason being the denser muscle mass in men and the clinical manifestation (muscular rigidity and fever secondary to hypermetabolism) being more visible than in women. In contrast, a meta-analysis by Gurrera et al. from 2017 concluded that NMS appeared equally in males and females, but more commonly in young adults.[@bib10] Women represented 50% of the cases in our study, and patients\' mean age was also compatible with the previous literature.[@bib8]

Sudden interruption of dopamine reduction is an important agent in the molecular mechanism of the development of NMS. This may result from termination of dopaminergic agent use with dopamine receptor antagonism mediated by neuroleptic or other pharmacological agents.[@bib4] Although typical neuroleptics are the most commonly implicated pharmacological agents in the literature, examination of the cases in our study revealed metoclopramide use in one and multiple pharmacological agent use in others, and the level of atypical antipsychotics use was higher compared to other drugs.[@bib11], [@bib12], [@bib13] The reason atypical antipsychotics are preferred by psychiatrists that they are superior to typical antipsychotics at side effects.

NMS may be difficult to diagnose since it begins with non-specific symptoms in the early period, such as unexplained tremor, muscular cramps, anxiety, confusion, agitation or catatonia, rather than the principal symptoms and findings such as fever, rigidity, mental state alterations and autonomic instability.[@bib4] In one case-controlled study, Berardi et al. particularly described psychomotor agitation, confusion, disorganized behavioral findings, and extrapyramidal findings as potential clinical risk factors for the development of NMS.[@bib14] Although there is evidence that the antidopaminergic effect of pharmacological agents is the mechanism underlying clinical and laboratory findings emerging in NMS, there are question marks concerning the mechanism by which agents with no effect on dopamine receptors give rise to the clinical manifestation.[@bib15], [@bib16] Analysis of the clinical characteristics of the cases in our study revealed no atypical findings other than mutism, dysphagia and incontinence, in addition to the classic findings. Hyperthermia and altered consciousness were determined in all patients and muscular rigidity was observed at a high level.

There are no 100% specific laboratory findings in NMS, although serum CK elevation increasing in association with muscular rigidity accompanies clinical findings. Serum CK levels exceeding 1000 IU/L and rising are generally correlated with severity of disease and prognosis.[@bib17], [@bib18] Other non-specific findings seen in NMS include metabolic acidosis, leukocytosis, increased lactate dehydrogenase and aminotransferases and electrolyte anomalies (hypocalcemia, hypomagnesemia, hypo-hypernatremia and hyperkalemia).[@bib19] The findings of this study correlated with literature.

Prognosis varies depending on the presence of complications such as rhabdomyolysis, renal failure, aspiration pneumonia, sepsis and pulmonary embolism. The mortality rate in NMS irrespective of early diagnosis and treatment is 5--20%, but this rises to 70% in the presence of complications.[@bib20], [@bib21], [@bib22] In this study, the mortality rate in patients diagnosed with NMS was approximately 17%. Shalev et al. evaluated 202 cases of NMS-associated mortality and identified rhabdomyolysis, myoglobinuria and renal failure as powerful predictors of mortality.[@bib7] Additionally, septic shock and respiratory and cardiac failure associated with infections developing secondary to hospitalization have also been reported as important risk factors for mortality.[@bib4] When we compared cases of death and recovery groups in terms of outcomes, age and blood pressure were statistically significantly higher in the death group. Advanced age and high blood pressure may therefore be interpreted as factors potentially affecting mortality. When death and recovery groups were compared in terms of laboratory values, CK, BUN and MPV values were statistically significantly higher in the death group. These findings support the idea that rhabdomyolysis and renal function impairment are important risk factors in terms of poor outcome. MPV values are involved in many studies as a current prognostic marker recently. Previous studies have linked MPV elevation with both poor prognosis and infarction area, particularly in patients with ischemic and hemorrhagic stroke, coronary artery disease and acute coronary syndrome.[@bib23] There is no study performed relationship between NMS and MPV values. The mechanism involved in this significant elevation observed in fatal cases of NMS is unclear, and further clinical studies involving larger case numbers regarding its potential predictive value for prognosis are needed.

5. Limitations {#sec5}
==============

There are limitations in this study. Due to the clinical rarity of NMS and the hospital\'s computerized database going back only 10 years, we were only able to access data for patients with entered ICD-10 diagnoses. The retrospective nature of the study also limited our access to all the information in the patient files.

6. Conclusion {#sec6}
=============

In conclusion, despite being a rare disease, NMS is a life-threatening condition in terms of clinical course and outcome that develops in association with neuroleptic and non-neuroleptic drug use. Atypical antipsychotic drug use was most commonly observed in the NMS cases assessed in this study, and advanced age and high CK, BUN and MPV values may be potential risk factors for mortality.
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[^1]: According to Mann Whitney *U* test.

[^2]: *Abbreviations* (MD: Median, Min: Minimum, Max: Maximum, NR: Normal Range, GCS: Glasgow Coma Scale, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, BUN: Blood Urea Nitrogen, Cre: Creatinine AST: Aspartate Aminotranferase, ALT: Alanine Aminotranferase WBC: White Blood Cell, CK: Creatine Kinase, LDH: Lactate Dehydrogenase, MPV: Mean Platelet Volume, RDW: Red Cell Distribution Width, NLR: Neutrophil Lymphocyte Ratio).
